Reversing Diabetes with blood pressure drug Verapamil: Verapamil [brand name: (Calan, Isoptin, Verelan)], a calcium channel blocker, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 8/May/2019, 8.19 am

Autologous blood transfusion as a curative therapy for chronic pain: Autologous blood transfusion increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 8/May/2019, 7.31 am
May 8, 2019
Features of Snapseed for Mac Devices
May 9, 2019
Show all

Introduction: What they say

A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that “miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function.” This research paper was published, in the 3 November 2017 issue of the journal “Diabetes” [One of the best research journals in diabetic research with an I.F of 10 plus], by Prof. Shalev A, Jo S and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Reversing Diabetes with blood pressure drug Verapamil: Verapamil [brand name: (Calan, Isoptin, Verelan)], a calcium channel blocker, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (4) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Prof. Shalev A’s research team has recently shown that:(1) MiRNA-204, the highly expressed miRNA in ß-cells, inhibits GLP1R expression; (2) deletion of miR-204: (a) increases cAMP production; (b) increases insulin secretion; (c) augments response to GLP1R activators or agonists; and (d) protects against diabetes; (3) deletion of thioredoxin-interacting protein, the upstream regulator of miR-204, (a) increases GLP1R expression; (b) ameliorates glucose intolerance; (c) improves cAMP production; (d) increases insulin secretion; and (e) protects against diabetes, suggesting that decreasing the expression of MiR-204 or its upstream regulator thioredoxin-interacting protein may promote insulin sensitivity, and alleviate TIIDM.


From Research findings to Therapeutic opportunity:

It has been shown recently that  blood pressure drug verapamil may aid in the treatment of Type I diabetes. However, the mechanism of action of this drug has remain largely unknown or not been demonstrated unequivocally.

This study provides, for the first time, mechanistic insights into how anti-hypertensive drug verapamil may aid in reversing diabetes. Verapamil, by increasing the expression of its target gene, it may increase the expression of GLP1R and Caveolin-1 (CAV-1). Thereby, it may: (1) increase pancreatic beta-cell proliferation; (2) increase the expression of genes that promote insulin sensitivity and insulin secretion; (3) promote weight loss; (4) augment energy expenditure; (5) decrease TXNIP levels and metabolic stress; and (6) promote energy homeostasis (Fig.1). Given the mechanistic basis as to how Verapamil may decrease blood glucose levels, medical practitioners/diabetologists may adopt this as a mode of curative therapy for TIIDM (Figure 2).

Figure 1. Mechanistic insights into how blood pressure drug Verapamil  aids in remission of diabetes.  Verapamil, by up-regulating its target genes, it may: a) increase CAV-1, GLP-1R, cAMP levels; b)  decrease TXNIP; c) increase insulin sensitivity; d) increase insulin secretion; and e) attenuate diabetes.

Figure 2. How blood pressure drug verapamil functions as a curative therapy for Diabetes.  Verapamil   may aid in remission of diabetes through induction of Cav1 and GLP1R.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How does verapamil increase the expression of GLP1R and CAV-1?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org  or http://newbioideas.com

Citation: Boominathan, L., Reversing Diabetes with blood pressure drug Verapamil: Verapamil [brand name: (Calan, Isoptin, Verelan)], a calcium channel blocker, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 8/May/2019, 8.19 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

 

Comments are closed.